I enjoy forming long-term relationships with my clients and having the opportunity to guide them through transformative matters and opportunities.
As co-chair of Foley Hoag’s Public Companies and Capital Markets practices, Stacie Aarestad specializes in corporate and securities law, and regularly acts as outside corporate counsel to public life sciences, technology and cannabis companies.
Stacie represents issuers in a broad range of capital market transactions, including public and private offerings of equity and debt securities; she also advises on various other matters affecting public companies and their officers and directors such as ongoing ’34 Act reporting obligations, corporate governance and related regulatory matters, Section 16 matters, insider trading regulations, executive compensation matters and ESG.
In addition to the 20+ years’ experience partnering with clients, Stacie co-leads the firm’s Women’s Forum which seeks to provide internal and external professional development and networking opportunities to women in order to facilitate change in the industry.
Boston University School of Law, J.D., magna cum laude, 1997
Colgate University, B.A., magna cum laude, Phi Beta Kappa, 1991
Bar and Court Admissions
BAR ADMISSIONS
Massachusetts
Experience Overview
Enanta Pharmaceuticals, Inc. (Nasdaq: ENTA), a clinical-stage biotechnology company, on its $74.8 million public offering, which included the underwriters’ full exercise of their option to purchase additional shares
Butterfly Network, Inc. (NYSE: BFLY), a digital health company, on its $86.9 million public offering of its Class A common stock
Zapata AI, an industrial Generative AI software company on the completion of its business combination with Andretti Acquisition Corp. (NYSE: WNNR), a special purpose acquisition company, which resulted in publicly traded combined company (Nasdaq: ZPTA and ZPTAW)
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases, in its sale to Syncona Limited (LON: SYNC) for approximately $23.5 million in cash ($0.34 per share)
Lantheus Holdings, Inc. (NASDAQ: LNTH), a company focused on developing innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, in a Rule 144A offering of $575 million aggregate principal amount of its 2.625% convertible senior notes due 2027
Pear Therapeutics, Inc. (Nasdaq: PEAR), a pioneer of prescription digital therapeutics, in a SPAC IPO/reverse merger of Pear Therapeutics, Inc. with and into a wholly owned subsidiary of Thimble Point Acquisition Corp. (THMA), with Pear Therapeutics, Inc. surviving the merger and THMA changing its name to Pear Therapeutics, Inc.
in closing its previously announced private placement of 8% Senior Secured Notes due 2026 for aggregate gross proceeds of US$350 million
in closing an underwritten public offering worth of approximately US$228 million of subordinate voting shares
in its C$115.5 million offering of subordinate voting shares
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases in a number of capital markets transactions, including:
an “at the market offering” program having an aggregate offering price of up to $50 million, with Cantor Fitzgerald & Co.
its underwritten public offering of 16,741,573 shares of its common stock, together with accompanying warrants to purchase 8,370,786 shares of common stock for gross proceeds of approximately $74.5 million
its sales agreement with Cantor Fitzgerald & Co. for an up to $25 million ATM offering
its $37.4 million underwritten public offering of common stock
Organogenesis Holdings Inc. (Nasdaq: ORGO) in multiple capital markets transactions, including
$64.7 million underwritten public offering of Class A common stock
$50.3 million underwritten public offering of Class A common stock
in its warrant exchange offer and consent solicitation
a SPAC IPO/reverse merger of Organogenesis Inc. with and into a wholly owned subsidiary of Avista Healthcare Public Acquisition Corp. (AHPAC), with Organogenesis Inc. surviving the merger and AHPAC changing its name to Organogenesis Holdings Inc.
Sensata Technologies, Inc., an indirect, wholly owned subsidiary of Sensata Technologies Holding plc (NYSE: ST), in its Rule 144A offering of $450 million in aggregate principal amount of 4.375% senior notes due 2030
Good Start Genetics in a merger with genetic information company Invitae Corporation (NYSE: NVTA)
Enanta Pharmaceuticals, Inc. (Nasdaq: ENTA) in its initial public offering of common stock
Zosano Pharma Corporation (Nasdaq: ZSAN)
$50.0 million underwritten public offering of common stock
$29.3 million underwritten public offering of common stock
$7.5 million PIPE of units (common stock and warrants) with warrants exercisable for an additional $14.4 million
Dyax Corp. (Nasdaq: DYAX) in its sale to Shire plc.
Dyax Corp. in public securities offerings including:
$230,000,000 underwritten public offering of common stock
$80,000,000 underwritten public offering of common stock
$65,000,000 underwritten public offering of common stock
$30,000,000 registered direct offering of common stock
$63,537,500 underwritten public offering of common stock
$21,000,000 underwritten public offering of common stock
$17,250,000 underwritten public offering of common stock
$50,000,000 Committed Equity Financing Facility with Azimuth Opportunity Ltd.
$44,300,000 underwritten public offering of common stock
Dyax Corp. in connection with secured loans including:
$65,000,000 loan agreement with Cowen Healthcare Royalty Partners, L.P., consisting of a $50,000,000 Tranche A loan and a $15,000,000 Tranche B loan, secured by Dyax’s phage display Licensing and Funded Research Program
$30,000,000 royalty interest assignment agreement with Paul Capital Partners
Bolt Technology Corporation (Nasdaq: BOLT) in its sale to Teledyne Technologies Incorporated (NYSE: TDY)
NewStar Financial, Inc. (Nasdaq: NEWS) in securities offerings:
$300,000,000 144A offering of 7.25% Senior Notes due 2020
$125,000,000 PIPE with institutional investors including, Corsair Capital, Union Square Partners and Och-Ziff Capital Management, Swiss Re and SAB Capital
Lamar Advertising Company (Nasdaq: LAMR) in its REIT conversion
Lamar Advertising Company and its wholly owned subsidiary Lamar Media Corp. in high yield and convertible debt offerings and tender offers including:
$400,000,000 144A offering of 5 3/4% Senior Notes due 2026
$510,000,000 144A offering of 5 ⅜% Senior Notes due 2024 with follow-on exchange offer
$535,000,000 144A offering of 5% Senior Subordinated Notes due 2023 with follow-on exchange offer
$500,000,000 144A offering of 5 ⅞% Senior Subordinated Notes due 2022 with follow-on exchange offer
$400,000,000 144A offering of 7 ⅞% Senior Subordinated Notes due 2018 with follow-on exchange offer
Cash Tender Offer and Consent Solicitation for all of Lamar’s then outstanding 7 ¼% Senior Subordinated Notes due 2013
Tender Offer to eligible employees and directors to exchange certain outstanding options to purchase the Company's Class A common stock for a lesser number of new options
Cash Tender Offers for all of Lamar’s then outstanding 2 ⅞% Convertible Notes due 2010—Series B
$350,000,000 144A offering of 9 ¾% Senior Notes due 2014 with follow-on exchange offer
$275,000,000 144A offering of 6 ⅝% Senior Subordinated Notes due 2015—Series C with follow-on exchange offer
Exchange Offer of a new series of 2 ⅞% Convertible Notes due 2010—Series B for all outstanding 2 ⅞% Convertible Notes due 2010
$216,000,000 144A offering of 6 ⅝% Senior Subordinated Notes due 2015—Series B with follow-on exchange offer
$400,000,000 144A offering of 6 ⅝% Senior Subordinated Notes due 2015 with follow-on exchange offer
"Top Women of Law," Massachusetts Lawyers Weekly, 2014
Selected for the Greater Boston Chamber of Commerce’s Executive Leadership Institute, 2014
Articles Editor, Boston University Law Review
Albert P. Pettoruto Memorial Award
INVOLVEMENT
Foley Hoag Women’s Forum, Co-Chair
Member, American Bar Association
Member, Massachusetts Bar Association
Member, Boston Bar Association
Past Member, Board of Directors, Massachusetts Biotechnology Education Foundation (2012-2023)
Other Events
Panelist, "Reopening the Capital Markets – What it Means for Life Sciences IPOs and M&A," NEHEN (March 2024)
Panelist, "Insights to Work Audit and Financial Literacy" – MassTLC Board-Read Bootcamp – (October 2023)
Panelist, “Multitrack Exit Strategies: M&A, IPO, Direct Listing, SPAC, or All of the Above?” – Boston Bar Association: 2021 Corporate Deals Conference (April 2021)
We use cookies to enhance user experience, improve functionality and performance, and for analysis of website traffic. By clicking “accept”, you agree to the use of cookies. For more information about our cookie policy and the information we collect, please review our Privacy Statement.
Foley Hoag
Email Disclaimer
Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK," you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you.
If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Foley Hoag.
